Tags : Acute Treatment of Migrane

Biotech

Lilly Files Lasmiditan to FDA for Acute Treatment of Migrane

Shots: •      The NDA filling is based on results of P-III SAMURAI and SPARTAN study assessing Lasmiditan vs PBO in patients with migrane with or without aura in adults •     The collective results of the study demonstrated safety and efficacy of Lasmiditan, meeting all 1EP & 2EP, showing greater percentage of patients free of their […]Read More